Submit Manuscript  

Article Details


Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment

[ Vol. 22 , Issue. 1 ]

Author(s):

Elisa Molinelli*, Valerio Brisigotti, Matteo Paolinelli and Annamaria Offidani   Pages 46 - 58 ( 13 )

Abstract:


Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet’s syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.

Keywords:

Bowel-associated dermatosis arthritis syndrome, neutrophilic dermatoses, pyoderma gangrenosum, Sweet`s syndrome, subcorneal pustular dermatoses, anti TNF, ustekinumab, secukinumab

Affiliation:

Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona

Graphical Abstract:



Read Full-Text article